Aclarion

Present pricing power is limited. In the U.S., Nociscan relies on Category III CPT codes 0609T–0612T, which facilitate billing but generally do not confer broad coverage or stable pricing. UK payers (AXA, Aviva, Vitality) have reimbursed scans in defined contexts, validating willingness to pay but not yet implying global pricing strength.

Over time, if CLARITY demonstrates materially superior outcomes and cost offsets (e.g., fewer failed fusions, improved selection), pricing leverage could improve with Category I conversion and payer contracts. Today, with minimal revenue and highly discretionary purchasing, effective pricing power is weak and latent rather than realized.